Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Flibanserin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 5/20 | 0.98 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.98 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.98 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.98 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.98 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.98 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.98 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.98 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.98 |
| ▸ | HTR7 known ✓ | P34969 | 8/20 | 0.70 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.57 |
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.56 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.56 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flibanserin SCHEMBL29399513 | 0.99 | HTR1A (1.00) | HTR1AABCB11ADRA2AADORA3CHRM1 | |
| Flibanserin SCHEMBL247579 | 0.99 | HTR1A (1.00) | HTR1AABCB11ADRA2AADORA3CHRM1 | |
| Flibanserin SCHEMBL30249132 | 0.99 | HTR1A (1.00) | HTR1AABCB11ADRA2AADORA3CHRM1 | |
| Flibanserin SCHEMBL2526226 | 0.98 | HTR1A (0.98) | HTR1AABCB11ADRA2AADORA3CHRM1 | |
| Flibanserin SCHEMBL19743166 | 0.98 | HTR1A (0.98) | HTR1AABCB11ADRA2AADORA3CHRM1 | |
| Flibanserin SCHEMBL19743151 | 0.98 | HTR1A (0.98) | HTR1AABCB11ADRA2AADORA3CHRM1 | |
| SCHEMBL8123196 | 0.95 | HTR1A (0.92) | HTR1AABCB11ADRA2AADORA3CHRM1 | |
| Flibanserin SCHEMBL2525812 | 0.94 | HTR1A (0.90) | HTR1AABCB11ADRA2AADORA3CHRM1 | |
| Flibanserin SCHEMBL2521706 | 0.94 | HTR1A (0.90) | HTR1AABCB11ADRA2AADORA3CHRM1 | |
| SCHEMBL8121051 | 0.93 | HTR1A (0.88) | HTR1AABCB11ADRA2AADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107235913-B | Method for efficiently manufacturing high-quality flibanserin on industrial scale | 苏州科伦药物研究有限公司 | 2020-07-10 | — | — | CN | claimed |
| CN-111303043-A | Preparation method of flibanserin hydrochloride | 武汉万知化工医药有限公司 | 2020-06-19 | — | — | CN | claimed |
| CN-109232434-A | A kind of new method synthesizing flibanserin | 湖北大学 | 2019-01-18 | — | — | CN | claimed |
| US-9546141-B2 | Salts | SPROUT PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | claimed |
| US-20120322810-A9 | NEW SALTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | claimed |
| US-20120122883-A1 | NEW SALTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-17 | — | — | US | claimed |
| EP-2376457-A2 | CRYSTALLINE SALT FORMS OF FLIBANSERINE | Boehringer Ingelheim International GmbH (DE) | 2011-10-19 | — | — | EP | claimed |
| WO-2010146595-A2 | NOVEL POLYMORPHS OF FLIBANSERIN HYDROCHLORIDE | SYMED LABS LIMITED (IN) | 2010-12-23 | — | — | WO | claimed |
| WO-2010079045-A2 | NEW SALTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-15 | — | — | WO | claimed |
| CN-113683570-A | New crystal form of flibanserin, preparation method and application thereof | 孟晓明 | 2021-11-23 | — | — | CN | disclosed |
| US-20210308129-A1 | TREATING SEXUAL DESIRE DISORDERS WITH FLIBANSERIN | SPROUT PHARMACEUTICALS INC (US) | 2021-10-07 | — | — | US | disclosed |
| US-11058683-B2 | Treating sexual desire disorders with flibanserin | SPROUT PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210069185-A1 | USE OF FLIBANSERIN IN THE TREATMENT OF OBESITY | HOLLAND, ANNE | 2021-03-11 | — | — | US | disclosed |
| US-10874668-B2 | Use of Flibanserin in the treatment of obesity | SPROUT PHARMACEUTICALS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20050239798-A1 | Method for the treatment of premenstrual and other female sexual disorders | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | US | disclosed |
| US-20040180904-A1 | Novel use of 2h-benzimidazol-2-one, 1,3-Dihydro-1-(2{4-[3-(trifluoromethyl)phenyl]-1-piperazinyl}ethyl)-and its physiologically acceptable addition salts | BECK JURGEN K (DE) | 2004-09-16 | — | — | US | disclosed |
| EP-1446122-A1 | USE OF FLIBANSERIN IN THE TREATMENT OF SEXUAL DISORDERS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003035072-A1 | USE OF FLIBANSERIN IN THE TREATMENT OF SEXUAL DISORDERS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-05-01 | — | — | WO | disclosed |
| WO-2002092088-A2 | NOVEL USE OF 2H-BENZIMIDAZOL-2-ONE, 1,3-DIHADRO-1-(2{4-{3-(TRIFLUOROMETHYL}PHENYL]-1-PIPERAZINYL}ETHYL)- AND ITS PHYSIOLOGICALLY ACCEPTABLE ACID ADDITION SALTS | BECK JUERGEN K (DE) | 2002-11-21 | — | — | WO | disclosed |
| EP-1256343-A1 | Flibanserin for the treatment of extrapyramidal movement disorders | Beck, Jürgen K. Dr. (DE) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122883-A1 | NEW SALTS | FLNB, FLNA, SLC10A1 | HTR1A 1165/4885ADRA2A 900/4885CHRM1 2278/4885 |
| US-10874668-B2 | Use of Flibanserin in the treatment of obesity | FABP4, FLNB, GPR119 | HTR1A 644/4885ADRA2A 800/4885CHRM1 1961/4885 |
| US-20120322810-A9 | NEW SALTS | FLNB, FLNA, SLC10A1 | HTR1A 1165/4885ADRA2A 900/4885CHRM1 2278/4885 |
| US-20040180904-A1 | Novel use of 2h-benzimidazol-2-one, 1,3-Dihydro-1-(2{4-[3-(trifluoromethyl)phenyl]-1-piperazinyl}ethyl)-and its physiologically acceptable addition salts | PARK7, IDO1, SNCA | HTR1A 242/4885ADRA2A 1108/4885CHRM1 1140/4885 |
| US-11058683-B2 | Treating sexual desire disorders with flibanserin | SLC6A3, FSHR, LPXN | HTR1A 155/4885ADRA2A 351/4885CHRM1 1331/4885 |
| US-20210069185-A1 | USE OF FLIBANSERIN IN THE TREATMENT OF OBESITY | FABP4, FLNB, GPR119 | HTR1A 644/4885ADRA2A 800/4885CHRM1 1961/4885 |
| US-20210308129-A1 | TREATING SEXUAL DESIRE DISORDERS WITH FLIBANSERIN | SLC6A3, FSHR, LPXN | HTR1A 155/4885ADRA2A 351/4885CHRM1 1331/4885 |
| US-20050239798-A1 | Method for the treatment of premenstrual and other female sexual disorders | FLNB, FSHR, CYP17A1 | HTR1A 447/4885ADRA2A 1467/4885CHRM1 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.